Compare TITN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | IMMP |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.9M | 410.7M |
| IPO Year | 2007 | 2012 |
| Metric | TITN | IMMP |
|---|---|---|
| Price | $16.30 | $0.40 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $21.50 | $5.50 |
| AVG Volume (30 Days) | 130.8K | ★ 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,702,122,000.00 | N/A |
| Revenue This Year | N/A | $382.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.50 | $0.40 |
| 52 Week High | $21.75 | $3.53 |
| Indicator | TITN | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 13.19 |
| Support Level | $15.32 | N/A |
| Resistance Level | $16.94 | $1.90 |
| Average True Range (ATR) | 0.82 | 0.12 |
| MACD | -0.42 | -0.27 |
| Stochastic Oscillator | 2.51 | 0.24 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through the following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.